Cargando…

Inhibition of Experimental Choroidal Neovascularization by a Novel Peptide Derived from Calreticulin Anti-Angiogenic Domain

Choroidal neovascularization (CNV) is a key pathological feature of several leading causes of vision loss including neovascular age-related macular degeneration. Here, we show that a calreticulin anti-angiogenic domain (CAD)-like peptide 27, CAD27, inhibited in vitro angiogenic activities, including...

Descripción completa

Detalles Bibliográficos
Autores principales: Bee, Youn-Shen, Ma, Yi-Ling, Chen, Jinying, Tsai, Pei-Jhen, Sheu, Shwu-Jiuan, Lin, Hsiu-Chen, Huang, Hu, Liu, Guei-Sheung, Tai, Ming-Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6213176/
https://www.ncbi.nlm.nih.gov/pubmed/30274378
http://dx.doi.org/10.3390/ijms19102993
_version_ 1783367709752295424
author Bee, Youn-Shen
Ma, Yi-Ling
Chen, Jinying
Tsai, Pei-Jhen
Sheu, Shwu-Jiuan
Lin, Hsiu-Chen
Huang, Hu
Liu, Guei-Sheung
Tai, Ming-Hong
author_facet Bee, Youn-Shen
Ma, Yi-Ling
Chen, Jinying
Tsai, Pei-Jhen
Sheu, Shwu-Jiuan
Lin, Hsiu-Chen
Huang, Hu
Liu, Guei-Sheung
Tai, Ming-Hong
author_sort Bee, Youn-Shen
collection PubMed
description Choroidal neovascularization (CNV) is a key pathological feature of several leading causes of vision loss including neovascular age-related macular degeneration. Here, we show that a calreticulin anti-angiogenic domain (CAD)-like peptide 27, CAD27, inhibited in vitro angiogenic activities, including tube formation, migration of endothelial cells, and vascular sprouting from rat aortic ring explants. In a rat model of laser-induced CNV, we demonstrate that intravitreal injection of CAD27 significantly attenuated the formation of CNV lesions as measured via fundus fluorescein angiography and choroid flat-mounts (19.5% and 22.4% reductions at 10 μg and 20 μg of CAD27 injected, respectively). Similarly, the reduction of CNV lesions was observed in rats that had received topical applications of CAD27 (choroid flat-mounts: 17.9% and 32.5% reductions at 10 μg/mL and 20 μg/mL of CAD27 instilled, respectively). Retinal function was unaffected, as measured using electroretinography in both groups receiving interareal injection or topical applications of CAD27 for at least fourteen days. These findings show that CAD27 can be used as a potential therapeutic alternative for targeting CNV in diseases such as neovascular age-related macular degeneration.
format Online
Article
Text
id pubmed-6213176
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-62131762018-11-14 Inhibition of Experimental Choroidal Neovascularization by a Novel Peptide Derived from Calreticulin Anti-Angiogenic Domain Bee, Youn-Shen Ma, Yi-Ling Chen, Jinying Tsai, Pei-Jhen Sheu, Shwu-Jiuan Lin, Hsiu-Chen Huang, Hu Liu, Guei-Sheung Tai, Ming-Hong Int J Mol Sci Article Choroidal neovascularization (CNV) is a key pathological feature of several leading causes of vision loss including neovascular age-related macular degeneration. Here, we show that a calreticulin anti-angiogenic domain (CAD)-like peptide 27, CAD27, inhibited in vitro angiogenic activities, including tube formation, migration of endothelial cells, and vascular sprouting from rat aortic ring explants. In a rat model of laser-induced CNV, we demonstrate that intravitreal injection of CAD27 significantly attenuated the formation of CNV lesions as measured via fundus fluorescein angiography and choroid flat-mounts (19.5% and 22.4% reductions at 10 μg and 20 μg of CAD27 injected, respectively). Similarly, the reduction of CNV lesions was observed in rats that had received topical applications of CAD27 (choroid flat-mounts: 17.9% and 32.5% reductions at 10 μg/mL and 20 μg/mL of CAD27 instilled, respectively). Retinal function was unaffected, as measured using electroretinography in both groups receiving interareal injection or topical applications of CAD27 for at least fourteen days. These findings show that CAD27 can be used as a potential therapeutic alternative for targeting CNV in diseases such as neovascular age-related macular degeneration. MDPI 2018-09-30 /pmc/articles/PMC6213176/ /pubmed/30274378 http://dx.doi.org/10.3390/ijms19102993 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bee, Youn-Shen
Ma, Yi-Ling
Chen, Jinying
Tsai, Pei-Jhen
Sheu, Shwu-Jiuan
Lin, Hsiu-Chen
Huang, Hu
Liu, Guei-Sheung
Tai, Ming-Hong
Inhibition of Experimental Choroidal Neovascularization by a Novel Peptide Derived from Calreticulin Anti-Angiogenic Domain
title Inhibition of Experimental Choroidal Neovascularization by a Novel Peptide Derived from Calreticulin Anti-Angiogenic Domain
title_full Inhibition of Experimental Choroidal Neovascularization by a Novel Peptide Derived from Calreticulin Anti-Angiogenic Domain
title_fullStr Inhibition of Experimental Choroidal Neovascularization by a Novel Peptide Derived from Calreticulin Anti-Angiogenic Domain
title_full_unstemmed Inhibition of Experimental Choroidal Neovascularization by a Novel Peptide Derived from Calreticulin Anti-Angiogenic Domain
title_short Inhibition of Experimental Choroidal Neovascularization by a Novel Peptide Derived from Calreticulin Anti-Angiogenic Domain
title_sort inhibition of experimental choroidal neovascularization by a novel peptide derived from calreticulin anti-angiogenic domain
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6213176/
https://www.ncbi.nlm.nih.gov/pubmed/30274378
http://dx.doi.org/10.3390/ijms19102993
work_keys_str_mv AT beeyounshen inhibitionofexperimentalchoroidalneovascularizationbyanovelpeptidederivedfromcalreticulinantiangiogenicdomain
AT mayiling inhibitionofexperimentalchoroidalneovascularizationbyanovelpeptidederivedfromcalreticulinantiangiogenicdomain
AT chenjinying inhibitionofexperimentalchoroidalneovascularizationbyanovelpeptidederivedfromcalreticulinantiangiogenicdomain
AT tsaipeijhen inhibitionofexperimentalchoroidalneovascularizationbyanovelpeptidederivedfromcalreticulinantiangiogenicdomain
AT sheushwujiuan inhibitionofexperimentalchoroidalneovascularizationbyanovelpeptidederivedfromcalreticulinantiangiogenicdomain
AT linhsiuchen inhibitionofexperimentalchoroidalneovascularizationbyanovelpeptidederivedfromcalreticulinantiangiogenicdomain
AT huanghu inhibitionofexperimentalchoroidalneovascularizationbyanovelpeptidederivedfromcalreticulinantiangiogenicdomain
AT liugueisheung inhibitionofexperimentalchoroidalneovascularizationbyanovelpeptidederivedfromcalreticulinantiangiogenicdomain
AT taiminghong inhibitionofexperimentalchoroidalneovascularizationbyanovelpeptidederivedfromcalreticulinantiangiogenicdomain